{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:09:02Z","timestamp":1753877342492,"version":"3.41.2"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institutes on Drug Abuse","doi-asserted-by":"crossref","award":["R01 DA043337"],"award-info":[{"award-number":["R01 DA043337"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Springer and Shaw","award":["R61\/R33 DA047037"],"award-info":[{"award-number":["R61\/R33 DA047037"]}]},{"name":"Springer, Kluger, and Ho","award":["DP1 DA056106","K02 DA032322"],"award-info":[{"award-number":["DP1 DA056106","K02 DA032322"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Persons who inject drugs are at increased risk for acquiring hepatitis C virus (HCV). Medications for opioid use disorder (MOUD) are associated with reduced injection drug use (IDU) frequency among persons with opioid use disorder (OUD). However, whether HCV treatment uptake or changes in IDU frequency differ by HIV serostatus among persons receiving MOUD is incompletely understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A secondary analysis was performed of data collected from 2 prospective cohort studies of participants with (PWH) or without HIV with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\u2013diagnosed OUD who were initiated on methadone, buprenorphine, or naltrexone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 129 participants, 78 (60.5%) were HCV antibody positive. PWH underwent increased HCV viral load testing (76.7% vs 43.3%; P = .028), but HCV treatment rates did not differ (17.6% vs 10.0%; P = .45) by HIV status. Participants without HIV reported a greater reduction in mean opioid IDU at 90 days (10.7 vs 2.0 fewer days out of 30; P &amp;lt; .001), but there were no group differences at 90 days. Stimulant use did not differ between groups. Urine opioid positivity declined from baseline to 90 days among the entire cohort (61.4% to 38.0%; P &amp;lt; .001) but did not differ by HIV serostatus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PWH who received MOUD underwent higher rates of follow-up HCV testing, but HCV treatment rates did not significantly differ by HIV serostatus. Participants without HIV on MOUD reported a greater reduction in opioid IDU. Improved integration of concomitant OUD with HCV and HIV screening, linkage to care, and treatment are needed for persons without HIV.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac624","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:49:33Z","timestamp":1668448173000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder"],"prefix":"10.1093","volume":"9","author":[{"given":"Audun J","family":"Lier","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Northport VA Medical Center , Northport, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Vander Wyk","sequence":"additional","affiliation":[{"name":"Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine , New Haven, Connecticut , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Di Paola","sequence":"additional","affiliation":[{"name":"AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine , New Haven, Connecticut , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6318-1000","authenticated-orcid":false,"given":"Sandra A","family":"Springer","sequence":"additional","affiliation":[{"name":"AIDS Program , , New Haven, Connecticut , USA"},{"name":"Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine , , New Haven, Connecticut , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"2023051616004265400_ofac624-B1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"2023051616004265400_ofac624-B2","first-page":"3","article-title":"Risk factors for the transmission of hepatitis C","volume":"24","author":"Zeuzem","year":"1996","journal-title":"J Hepatol"},{"key":"2023051616004265400_ofac624-B3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","article-title":"Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review","volume":"372","author":"Mathers","year":"2008","journal-title":"Lancet"},{"key":"2023051616004265400_ofac624-B4","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged \u226430 years\u2014Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20132012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023051616004265400_ofac624-B5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13011-021-00350-5","article-title":"\u2018Resurgent\u2019, \u2018twin\u2019 or \u2018silent\u2019 epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America","volume":"16","author":"Fischer","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2023051616004265400_ofac624-B6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"2023051616004265400_ofac624-B7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jvh.12338","article-title":"HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact","volume":"22","author":"Martin","year":"2015","journal-title":"J Viral Hepat"},{"key":"2023051616004265400_ofac624-B8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0956462419832750","article-title":"Hepatitis C care cascade in HIV patients at an urban clinic in the early direct-acting antiviral era","volume":"30","author":"Ma","year":"2019","journal-title":"Int J STD AIDS"},{"key":"2023051616004265400_ofac624-B9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijid.2021.02.068","article-title":"The hepatitis C cascade of care in the Belgian HIV population: one step closer to elimination","volume":"105","author":"Busschots","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023051616004265400_ofac624-B10","doi-asserted-by":"crossref","first-page":"e102883","DOI":"10.1371\/journal.pone.0102883","article-title":"The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care","volume":"9","author":"Cachay","year":"2014","journal-title":"PLoS One"},{"key":"2023051616004265400_ofac624-B11","doi-asserted-by":"crossref","first-page":"e25013","DOI":"10.1002\/jia2.25013","article-title":"Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada","volume":"20","author":"Saeed","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2023051616004265400_ofac624-B12","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:a:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"2023051616004265400_ofac624-B13","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1111\/add.15459","article-title":"Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data","volume":"116","author":"Palmateer","year":"2021","journal-title":"Addiction"},{"key":"2023051616004265400_ofac624-B14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QAI.0000000000000165","article-title":"HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial","volume":"66","author":"Woody","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023051616004265400_ofac624-B15","first-page":"224","article-title":"The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings","volume":"81","author":"Ball","year":"1988","journal-title":"NIDA Res Monogr"},{"key":"2023051616004265400_ofac624-B16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jsat.2006.04.005","article-title":"HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone","volume":"31","author":"Lott","year":"2006","journal-title":"J Subst Abuse Treat"},{"key":"2023051616004265400_ofac624-B17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial","volume":"62","author":"Marsch","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"2023051616004265400_ofac624-B18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0b013e3181d916db","article-title":"HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study","volume":"55","author":"Meade","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023051616004265400_ofac624-B19","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0140-6736(08)60954-X","article-title":"Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial","volume":"371","author":"Schottenfeld","year":"2008","journal-title":"Lancet"},{"key":"2023051616004265400_ofac624-B20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","article-title":"Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors","volume":"35","author":"Sullivan","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"2023051616004265400_ofac624-B21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13722-021-00266-2","article-title":"The impact of methamphetamine\/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review","volume":"16","author":"Frost","year":"2021","journal-title":"Addict Sci Clin Pract"},{"key":"2023051616004265400_ofac624-B22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jsat.2017.01.017","article-title":"Examination of the hepatitis C virus care continuum among individuals with an opioid use disorder in substance use treatment","volume":"76","author":"Brown","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2023051616004265400_ofac624-B23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.cgh.2015.02.022","article-title":"Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse","volume":"13","author":"Ho","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023051616004265400_ofac624-B24","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023051616004265400_ofac624-B25","doi-asserted-by":"crossref","first-page":"100704","DOI":"10.1016\/j.conctc.2021.100704","article-title":"Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder","volume":"21","author":"Biondi","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"2023051616004265400_ofac624-B26","doi-asserted-by":"crossref","first-page":"100866","DOI":"10.1016\/j.conctc.2021.100866","article-title":"Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence","volume":"24","author":"Schultheis","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"2023051616004265400_ofac624-B27","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2023051616004265400_ofac624-B28","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2105\/AJPH.86.7.966","article-title":"Recovery from alcohol problems with and without treatment: prevalence in two population surveys","volume":"86","author":"Sobell","year":"1996","journal-title":"Am J Public Health"},{"key":"2023051616004265400_ofac624-B29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1046\/j.1360-0443.2002.00185.x","article-title":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility","volume":"97","author":"WHO ASSIST Working Group","year":"2002","journal-title":"Addiction"},{"key":"2023051616004265400_ofac624-B30","doi-asserted-by":"crossref","first-page":"e0230121","DOI":"10.1371\/journal.pone.0230121","article-title":"The Health Resources and Services Administration's Ryan White HIV\/AIDS Program in rural areas of the United States: geographic distribution, provider characteristics, and clinical outcomes","volume":"15","author":"Klein","year":"2020","journal-title":"PLoS One"},{"key":"2023051616004265400_ofac624-B31","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1093\/infdis\/jiz673","article-title":"Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA's Advocacy Agenda","volume":"222","author":"Springer","year":"2020","journal-title":"J Infect Dis"},{"key":"2023051616004265400_ofac624-B32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2020.2559","article-title":"Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the National Academies of Sciences, Engineering, and Medicine","volume":"324","author":"Springer","year":"2020","journal-title":"JAMA"},{"author":"The National Academies of Sciences, Engineering, Medicine","key":"2023051616004265400_ofac624-B33","article-title":"Examination of the integration of opioid and infectious disease prevention efforts in select programs. Available at"},{"key":"2023051616004265400_ofac624-B34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2017.01.015","article-title":"Retention in buprenorphine treatment is associated with improved HCV care outcomes","volume":"75","author":"Norton","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2023051616004265400_ofac624-B35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1377\/hlthaff.2013.1087","article-title":"New evidence on the Affordable Care Act: coverage impacts of early Medicaid expansions","volume":"33","author":"Sommers","year":"2014","journal-title":"Health Aff (Millwood)"},{"volume-title":"A National Strategy for the Elimination of Hepatitis B and C: A Phase Two Report","year":"2017","author":"The National Academies of Sciences, Engineering, Medicine","key":"2023051616004265400_ofac624-B36"},{"author":"The Centers for Medicaid and CHIP Services","key":"2023051616004265400_ofac624-B37","article-title":"Medication assisted treatment for substance use disorders, CMCS information bulletin. Available at"},{"author":"APT Foundation","key":"2023051616004265400_ofac624-B38","article-title":"Our mission"},{"key":"2023051616004265400_ofac624-B39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clpt.2003.09.004","article-title":"Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence","volume":"75","author":"Montoya","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"2023051616004265400_ofac624-B40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13722-022-00299-1","article-title":"Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community","volume":"17","author":"Biondi","year":"2022","journal-title":"Addict Sci Clin Pract"},{"key":"2023051616004265400_ofac624-B41","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"author":"National Institute on Drug Abuse","key":"2023051616004265400_ofac624-B42"},{"key":"2023051616004265400_ofac624-B43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial","volume":"78","author":"Springer","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023051616004265400_ofac624-B44","doi-asserted-by":"crossref","first-page":"e38335","DOI":"10.1371\/journal.pone.0038335","article-title":"Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners","volume":"7","author":"Springer","year":"2012","journal-title":"PLoS One"},{"key":"2023051616004265400_ofac624-B45","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023051616004265400_ofac624-B46","doi-asserted-by":"crossref","first-page":"103570","DOI":"10.1016\/j.drugpo.2021.103570","article-title":"Treatment of hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: the potential role of telehealth, medications for opioid use disorder and minimal demands on patients","volume":"101","author":"Sivakumar","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2023051616004265400_ofac624-B47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0033354920969179","article-title":"Routine screening and linkage to care for hepatitis C virus in an urban safety-net health system 2017\u20132019","volume":"136","author":"Hunt","year":"2021","journal-title":"Public Health Rep"},{"key":"2023051616004265400_ofac624-B48","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M18-1203","article-title":"Integrating treatment at the intersection of opioid use disorder and infectious disease epidemics in medical settings: a call for action after a National Academies of Sciences, Engineering, and Medicine workshop","volume":"169","author":"Springer","year":"2018","journal-title":"Ann Intern Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac624\/47030429\/ofac624.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/11\/ofac624\/50344896\/ofac624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/11\/ofac624\/50344896\/ofac624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T18:02:57Z","timestamp":1684260177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac624\/6827344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac624","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,11,1]]},"article-number":"ofac624"}}